Clarification needed on the effects of FLACS

Article

More research required to clarify the short- and long-term effects of femtosecond laser-assisted cataract surgery (FLACS) on the corneal endothelium.

The authors of a new review in Current Opinion in Ophthalmology advocate for more research to clarify the short- and long-term effects of femtosecond laser-assisted cataract surgery (FLACS) on the corneal endothelium.

FLACS may reduce endothelial cell loss, they write, but the reduction most likely occurs only in the early postoperative period. Research to date has reached varying conclusions on FLACS’ ability to reduce endothelial cell loss, the authors note. Some studies point to the reduced amount of ultrasound energy required with FLACS. Others show no difference or less cell loss with FLACS than with standard phacoemulsification 1 to 3 months postoperatively. At 6 months, however, some studies have found that cell loss is similar regardless of technique used.

Further, newer advancements in surgical technique or technology - biaxial microincision surgery, the use of ultraviolet light in light-adjustable IOLs, and newer viscous - dispersives, for instance - show cell loss rates that are similar to or better than standard phaco.

“Viscous dispersives may offer equal or increased protection of the corneal endothelium during surgery compared with viscoelastic devices currently in wide use, but further studies are required to support these results,” they add.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Alfredo Sadun, MD, PhD, chief of Ophthalmology at the Doheny Eye Institute, University of California Los Angeles, shared exciting new research with the Eye Care Network during the Association for Research in Vision and Ophthalmology (ARVO) meeting on the subject of Leber hereditary optic neuropathy (LHON).
At this year's Association for Research in Vision and Ophthalmology (ARVO) meeting in Salt Lake City, Utah, Nitish Mehta, MD, shared highlights from his research documenting real-world results of aflibercept 8 mg for patients with diabetic macular oedema.
ARVO 2025: Anat Loewenstein, MD, shares data from herself and her colleagues on meeting needs of patients with diabetic retinopathy
At the American Society of Cataract and Refractive Surgeons annual meeting, Sheng Lim, MD, FRCOphth discusses the benefit of endoscopic cyclophotocoagulation for patients with primary open angle glaucoma and cataracts in the CONCEPT study
A photo of Seville, Spain, with the Congress on Controversies in Ophthalmology logo superimposed on it. Image credit: ©francovolpato – stock.adobe.com; logo courtesy COPHy
Anat Loewenstein, MD, Professor and Director, Department of Ophthalmology, Tel Aviv Medical Center, discusses the Congress on Controversies in Ophthalmology (COPHy)
Anat Loewenstein, MD, speaks about the 22nd Annual Angiogenesis, Exudation, and Degeneration Meeting in February 2025 and shares her global forecast for AI-driven home OCT
© 2025 MJH Life Sciences

All rights reserved.